Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
30.2M
-
Shares change
-
+1.93M
-
Total reported value, excl. options
-
$528M
-
Value change
-
+$32.3M
-
Number of buys
-
56
-
Number of sells
-
-42
-
Price
-
$17.52
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q1 2018
113 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q1 2018.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.2M shares
of 108M outstanding shares and own 27.84% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.75M shares), FRANKLIN RESOURCES INC (2.58M shares), FMR LLC (2.56M shares), BlackRock Inc. (2.11M shares), Polar Capital LLP (1.65M shares), Vivo Capital, LLC (1.65M shares), Sofinnova Ventures Inc (1.54M shares), D. E. Shaw & Co., Inc. (1.24M shares), VANGUARD GROUP INC (1.17M shares), and Balyasny Asset Management LLC (986K shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.